UNICREDIT BANK/CALL/ASTRAZENECA/15000/0.1/18.06.25 | Market Closed - Börse Stuttgart 19:58:39 17/05/2024 BST | ||
| 0.46 EUR | -4.17% |
|
| Current month | +4.55% | ||
| 1 month | +100.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 0.46 | -4.17% |
| 16/05/24 | 0.48 | -2.04% |
| 15/05/24 | 0.49 | -5.77% |
| 14/05/24 | 0.52 | -1.89% |
| 13/05/24 | 0.53 | -3.64% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 07:58 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HD1H8C |
| ISIN | DE000HD1H8C4 |
| Date issued | 28/12/2023 |
| Strike | 15,000 p |
| Maturity | 18/06/2025 (397 Days) |
| Parity | 10 : 1 |
| Emission price | 0.29 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.59 € |
|---|---|
| Lowest since issue | 0.063 € |
| Spread | 0.03 € |
| Spread % | 6.12% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.9
USD
Average target price
167.6
USD
Spread / Average Target
+8.90%
- Stock Market
- Warrants
- Warrant
